Lavengratinib
Lavengratinib (ABSK061) is a FGFR2/FGFR3 inhibitor. Lavengratinib selectively inhibits FGFR2 and FGFR3 signaling pathways and reduces the risk of FGFR1-mediated hyperphosphatemia. Lavengratinib is suitable for research on advanced solid tumors (including cholangiocarcinoma, gastric cancer, non-small cell lung cancer, cervical cancer and urothelial cancer).
For research use only. We do not sell to patients.
- CAS No.: 2412854-49-8
- Formula: C26H27Cl2N5O4
- Molecular Weight:544.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
FGFR2 |
FGFR3 |
Resistance to Lavengratinib (ABSK061) involves secondary mutations in the kinase domains of FGFR2/3 and off-target alterations in the RTK/RAS and DDR pathways[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2412854-49-8
-
Molecular Weight 544.43
-
Formula C26H27Cl2N5O4
-
SMILES
O=C1C(C2=C(C(OC)=CC(OC)=C2Cl)Cl)=CC3=CN=C(C4=CN(CCN5CCOCC5)N=C4)C=C3N1C
-
Synonyms
ABSK061
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)